ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 4 to Schedule 13G with the SEC on November 13, 2026, disclosing beneficial ownership of 44,745,024 shares of Recursion Pharmaceuticals, Inc. Class A Common Stock as of September 30, 2026.

Key Highlights

  • Aggregate beneficial ownership: ARK Investment Management LLC and Catherine D. Wood each report beneficial ownership of 44,745,024 shares of Recursion Pharmaceuticals Class A Common Stock.
  • Percent of class: The 44,745,024 shares represent 8.36% of the class, according to the filing.
  • ARK voting power: ARK reports sole voting power over 42,796,887 shares and shared voting power over 548,854 shares.
  • Catherine D. Wood voting power: Wood reports sole voting power of 0 shares and shared voting power of 43,345,741 shares.
  • Dispositive power: ARK holds sole dispositive power over all 44,745,024 shares; Wood holds shared dispositive power over the same 44,745,024 shares, with 0 sole dispositive power.
  • Triggering event date: The date of event requiring this filing is stated as September 30, 2026.

ARK and Wood Disclose 8.36% Stake in Recursion Pharmaceuticals

ARK Investment Management LLC, a Delaware-organized investment adviser, and Catherine D. Wood, a United States citizen serving as Chief Executive Officer and Chief Investment Officer of ARK, jointly filed Amendment No. 4 to Schedule 13G regarding their holdings in Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX). The filing covers Class A Common Stock with CUSIP number 75629V104, and was signed by both parties on November 13, 2026, with a triggering event date of September 30, 2026.

According to the filing, the aggregate amount beneficially owned by each reporting person is 44,745,024 shares, representing 8.36% of the class. ARK reports sole voting power over 42,796,887 shares and shared voting power over 548,854 shares, while Wood reports no sole voting power and shared voting power over 43,345,741 shares. For dispositive authority, ARK holds sole dispositive power over 44,745,024 shares with no shared dispositive power, while Wood holds no sole dispositive power but reports shared dispositive power over the full 44,745,024 shares.

Both reporting persons certified, as stated in the filing, that the referenced securities "were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer." The filing lists the principal business address for both ARK and Catherine D. Wood as 200 Central Avenue, St. Petersburg, FL 33701, and identifies Recursion Pharmaceuticals' principal executive offices at 41 S Rio Grande Street, Salt Lake City, UT 84101.

What Was Disclosed

ARK Investment Management LLC and Catherine D. Wood filed Amendment No. 4 to Schedule 13G reporting combined beneficial ownership of 44,745,024 shares, or 8.36%, of Recursion Pharmaceuticals Class A Common Stock as of September 30, 2026.